207 related articles for article (PubMed ID: 25341025)
21. Penicillamine revisited: historic overview and review of the clinical uses and cutaneous adverse effects.
Ishak R; Abbas O
Am J Clin Dermatol; 2013 Jun; 14(3):223-33. PubMed ID: 23605177
[TBL] [Abstract][Full Text] [Related]
22. Detection of D-penicillamine in skin lesions in a case of dermal elastosis after a previous long-term treatment for Wilson's disease.
Neri I; Gurioli C; Raggi MA; Saracino MA; Morganti E; Bugamelli F; de Ponti F; Vaccari S; Patrizi A; Balestri R
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):383-386. PubMed ID: 24404914
[TBL] [Abstract][Full Text] [Related]
23. Concomitant immune-related events in Wilson disease: implications for monitoring chelator therapy.
Seessle J; Gotthardt DN; Schäfer M; Gohdes A; Pfeiffenberger J; Ferenci P; Stremmel W; Weiss KH
J Inherit Metab Dis; 2016 Jan; 39(1):125-30. PubMed ID: 26067812
[TBL] [Abstract][Full Text] [Related]
24. Generalized scleroderma-like induration associated with D-penicillamine elastosis perforans serpiginosa in Wilson's disease.
Atzori L; Ferreli C; Agosta D; Mou M; Coni P; Lachowicz JI; Pilloni L
Int J Dermatol; 2023 Feb; 62(2):246-249. PubMed ID: 35968714
[No Abstract] [Full Text] [Related]
25. "Lumpy-bumpy" elastic fibers in the skin and lungs of a patient with a penicillamine-induced elastosis perforans serpiginosa.
Bardach H; Gebhart W; Niebauer G
J Cutan Pathol; 1979 Aug; 6(4):243-52. PubMed ID: 500870
[TBL] [Abstract][Full Text] [Related]
26. Penicillamine-induced degenerative dermatoses: report of a case and brief review of such dermatoses.
Iozumi K; Nakagawa H; Tamaki K
J Dermatol; 1997 Jul; 24(7):458-65. PubMed ID: 9267106
[TBL] [Abstract][Full Text] [Related]
27. Response to different therapeutic approaches in Wilson disease. A long-term follow up study.
Rodríguez B; Burguera J; Berenguer M
Ann Hepatol; 2012; 11(6):907-14. PubMed ID: 23109455
[TBL] [Abstract][Full Text] [Related]
28. Elastosis perforans serpiginosa associated with pseudo-pseudoxanthoma elasticum during treatment of Wilson's disease with penicillamine.
Bécuwe C; Dalle S; Ronger-Savlé S; Skowron F; Balme B; Kanitakis J; Thomas L
Dermatology; 2005; 210(1):60-3. PubMed ID: 15604549
[TBL] [Abstract][Full Text] [Related]
29. Penicillamine: the treatment of first choice for patients with Wilson's disease.
Walshe JM
Mov Disord; 1999 Jul; 14(4):545-50. PubMed ID: 10435489
[No Abstract] [Full Text] [Related]
30. Comparative effectiveness of common therapies for Wilson disease: A systematic review and meta-analysis of controlled studies.
Appenzeller-Herzog C; Mathes T; Heeres MLS; Weiss KH; Houwen RHJ; Ewald H
Liver Int; 2019 Nov; 39(11):2136-2152. PubMed ID: 31206982
[TBL] [Abstract][Full Text] [Related]
31. [An unusual cutaneous reaction pattern as a side effect of penicillamine: elastosis perforans serpiginosa].
van Joost T; de Leeuw J
Ned Tijdschr Geneeskd; 1988 Mar; 132(11):501-3. PubMed ID: 2965796
[No Abstract] [Full Text] [Related]
32. Bullous pemphigoid induced by penicillamine in a patient with Wilson disease.
Popadic S; Skiljevic D; Medenica L
Am J Clin Dermatol; 2009; 10(1):36-8. PubMed ID: 19170410
[TBL] [Abstract][Full Text] [Related]
33. Elastosis perforans serpiginosa secondary to D-penicillamine therapy with coexisting cutis laxa.
Rosen LB; Muellenhoff M; Tran TT; Muhart M
Cutis; 2005 Jul; 76(1):49-53. PubMed ID: 16144289
[TBL] [Abstract][Full Text] [Related]
34. Penicillamine induced pseudo-pseudoxanthoma elasticum in a patient with Wilson's disease, which role plays the hepatologist?
Ibáñez-Samaniego L; Ochoa-Palominos A; Catalina-Rodríguez MV; Salcedo-Plaza M; Clemente-Ricote G
Rev Esp Enferm Dig; 2015 Mar; 107(3):190-1. PubMed ID: 25733050
[No Abstract] [Full Text] [Related]
35. Patient with late-onset Wilson's disease: deterioration with penicillamine.
Sohtaoglu M; Ergin H; Ozekmekçi S; Gökdemir S; Sonsuz A; Arici C
Mov Disord; 2007 Jan; 22(2):290-1. PubMed ID: 17083099
[No Abstract] [Full Text] [Related]
36. Epileptic status immediately after initiation of D-penicillamine therapy in a patient with Wilson's disease.
Berger B; Mader I; Damjanovic K; Niesen WD; Stich O
Clin Neurol Neurosurg; 2014 Dec; 127():122-4. PubMed ID: 25459257
[No Abstract] [Full Text] [Related]
37. Zinc treatment for symptomatic Wilson disease: moving forward by looking back.
Schilsky M
Hepatology; 2009 Nov; 50(5):1341-3. PubMed ID: 19877301
[No Abstract] [Full Text] [Related]
38. Hypothyroidism and dyshormonogenesis induced by D-penicillamine in children with Wilson's disease and healthy infants born to a mother with Wilson's disease.
Hanukoglu A; Curiel B; Berkowitz D; Levine A; Sack J; Lorberboym M
J Pediatr; 2008 Dec; 153(6):864-6. PubMed ID: 19014823
[TBL] [Abstract][Full Text] [Related]
39. Early onset of nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson's disease.
Siafakas CG; Jonas MM; Alexander S; Herrin J; Furuta GT
Am J Gastroenterol; 1998 Dec; 93(12):2544-6. PubMed ID: 9860423
[TBL] [Abstract][Full Text] [Related]
40. Oral complications associated with D-penicillamine treatment for Wilson disease: a clinicopathologic report.
Tovaru S; Parlatescu I; Dumitriu AS; Bucur A; Kaplan I
J Periodontol; 2010 Aug; 81(8):1231-6. PubMed ID: 20384464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
